Supreme Court To Take Drug Pricing Case

0 Shares

WASHINGTON (UPI) — The U.S. Supreme Court said it will rule in a case involving payments by pharmaceutical companies to rivals in return for delaying sales of generic drugs.

 

 

 

The Federal Trade Commission says the so-called pay-for-delay deals violate antitrust law, preserve monopolies and artificially jack up prices, the Los Angeles Times said Saturday.

 

 

 

The commission said 28 such agreements cost consumers and taxpayers at least $3.5 billion in 2011, the newspaper reported.

 

 

 

“When drug companies agree not to compete, consumers lose,” FTC Chairman Jon Leibowitz said.

 

 

 

Federal courts have upheld such deals in a number of cases, finding they constitute settlements of patent disputes.

 

 

 

The Supreme Court said Friday it would consider a case involving an agreement in which Solvay Pharmaceuticals Inc., which makes the testosterone booster AndroGel, agreed to pay Watson Pharmaceuticals Inc. more than $19 million a year in return for Watson’s agreement to hold a competitive drug off the market until 2015.

UPI - United Press International, Inc.

Since 1907, United Press International (UPI) has been a leading provider of critical information to media outlets, businesses, governments and researchers worldwide.